| Old Articles: <Older 1451-1460 Newer> |
|---|
 |
The Motley Fool
October 8, 2004
Charly Travers |
Genentech's Wealth Transfer Program Genentech's stock is even more expensive than you think.   |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
BusinessWeek
October 18, 2004
Gene G. Marcial |
Is Pfizer Eyeing Eyetech? Pfizer may buy Eyetech after its Macugen ophthalmology product is approved. And a Merrill Lynch analyst calls Eyetech stock "a buy," saying it should turn profitable in 2005, earning 19 cents a share, and 81 cents in 2006. |
BusinessWeek
October 18, 2004
John Carey |
"Off-Label" -- And Out Of Bounds? When drugmakers promote products for unproven uses, they may be courting trouble. How restrictive should the regulations be? |
The Motley Fool
October 7, 2004
Charly Travers |
Santarus Takes on Big Pharma Can this small drug company compete with the industry's giants? Santarus bolstered its marketing efforts with the signing of a very beneficial partnership with Otsuka America Pharmaceutical. |
The Motley Fool
October 7, 2004
Seth Jayson |
Painless? My Assets Another warning from dental tech firm Biolase Technology sends the stock down. |
The Motley Fool
October 7, 2004
Brian Gorman |
Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors. |
The Motley Fool
October 6, 2004
Rich Duprey |
Chiron Sneezes, Investors Catch Cold British authorities shut down the pharmaceutical's only U.S. flu vaccine manufacturing facility. This may in fact be an opportunity to scoop up a beleaguered stock at fire sale prices. |
The Motley Fool
October 5, 2004
Alyce Lomax |
No Cheer for Chiron A U.K. regulatory body suspended its manufacturing license because of contamination. The company's misstep adds up to another rough flu season. |
The Motley Fool
October 5, 2004
W.D. Crotty |
Lots of Profits in This Forest Drug manufacturer Forest Laboratories, down sharply from its high, offers value and growth. |
| <Older 1451-1460 Newer> Return to current articles. |
